We are live on
!
Find out more
DMK
David M. Knott Portfolio holdings
AUM
$275M
Turnover
23.21%
1-Year Est. Return
59.23%
This Fund
S&P 500
This Quarter
Est. Return
+7.86%
1 Year Est. Return
+59.23%
3 Year Est. Return
+80.95%
5 Year Est. Return
+223.18%
10 Year Est. Return
–
AUM
$234M
AUM Growth
-$5.63M
(-2.4%)
Cap. Flow
-$22.7M
Cap. Flow
% of AUM
-9.71%
Top 10 Holdings %
Top 10 Hldgs %
77.03%
Holding
114
New
24
Increased
15
Reduced
9
Closed
6
Avg Time Held
1.8
years
Top 10 Avg Time Held
1.8
years
Top 20 Avg Time Held
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DuPont de Nemours
DD
|
+$1.24M |
| 2 |
ATCO
Atlas Corp.
ATCO
|
+$963K |
| 3 |
Chiron Real Estate Inc Series A Preferred Stock
XRN.PRA
|
+$871K |
| 4 |
Kimberly-Clark
KMB
|
+$733K |
| 5 |
RXDX
Ignyta, Inc.
RXDX
|
+$698K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Ligand Pharmaceuticals
LGND
|
+$25.4M |
| 2 |
AGN
Allergan plc
AGN
|
+$2.3M |
| 3 |
Pfizer
PFE
|
+$1.93M |
| 4 |
AbbVie
ABBV
|
+$1.35M |
| 5 |
Du Pont De Nemours E I
DD
|
+$1.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.4% |
| 2 | Financials | 8.46% |
| 3 | Technology | 4.23% |
| 4 | Real Estate | 3.89% |
| 5 | Industrials | 3.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
IMMU
26
DELISTED
Immunomedics Inc
IMMU
| $915K | 0.39% |
65,483
-300
| -0.5% | -$2.99K |
2017 Q1
2 quarters
|
|
27
Verizon
VZ
$186B
| $906K | 0.39% |
18,311
| – | – |
2014 Q2
13 quarters
|
|
28
Apollo Global Management
APO
$65.9B
| $903K | 0.39% |
30,000
| – | – |
2017 Q2
1 quarter
|
|
29
DELISTED
Macquarie Infrastructure Holdings, LLC
MIC
| $888K | 0.38% |
12,300
| – | – |
2014 Q2
13 quarters
|
|
|
30
Chiron Real Estate Inc Series A Preferred Stock
XRN.PRA
$74.5M
| $878K | 0.38% |
+35,000
| New | +$871K |
2017 Q3
0 quarters
|
|
31
Future Fuel
FF
$243M
| $863K | 0.37% |
54,804
| – | – |
2013 Q2
17 quarters
|
|
32
AT&T
T
$161B
| $863K | 0.37% |
29,194
| – | – |
2014 Q2
13 quarters
|
|
33
Gilead Sciences
GILD
$193B
| $844K | 0.36% |
10,420
| – | – |
2015 Q4
7 quarters
|
|
|
RXDX
34
DELISTED
Ignyta, Inc.
RXDX
| $836K | 0.36% |
+67,700
| New | +$698K |
2017 Q3
0 quarters
|
|
|
STML
35
DELISTED
Stemline Therapeutics, Inc.
STML
| $832K | 0.36% |
74,992
+33,300
| +80% | +$313K |
2017 Q1
2 quarters
|
|
36
Ryman Hospitality Properties
RHP
$8.71B
| $775K | 0.33% |
12,400
| – | – |
2013 Q2
17 quarters
|
|
|
NVLN
37
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $768K | 0.33% |
109,184
| – | – |
2016 Q4
3 quarters
|
|
|
GBT
38
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $752K | 0.32% |
24,224
+11,500
| +90% | +$323K |
2017 Q2
1 quarter
|
|
|
SVC
39
Service Properties Trust
SVC
$796M
| $712K | 0.3% |
5,000
| – | – |
2015 Q1
10 quarters
|
|
|
40
Kimberly-Clark
KMB
$34.8B
| $706K | 0.3% |
+6,000
| New | +$733K |
2017 Q3
0 quarters
|
|
41
GE Aerospace
GE
$327B
| $693K | 0.3% |
5,984
| – | – |
2013 Q2
17 quarters
|
|
|
42
Chiron Real Estate Inc
XRN
$402M
| $691K | 0.3% |
15,400
| – | – |
2016 Q2
5 quarters
|
|
43
Weyerhaeuser
WY
$14.1B
| $681K | 0.29% |
20,000
| – | – |
2017 Q2
1 quarter
|
|
44
Wheeler Real Estate Investment Trust Series D Preferred Stock
WHLRD
| $680K | 0.29% |
30,000
| – | – |
2016 Q3
4 quarters
|
|
|
CNCE
45
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $664K | 0.28% |
+45,000
| New | +$653K |
2017 Q3
0 quarters
|
|
|
BLCM
46
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $658K | 0.28% |
5,698
+3,700
| +185% | +$389K |
2017 Q1
2 quarters
|
|
47
DELISTED
Dermira, Inc.
DERM
| $649K | 0.28% |
24,036
+5,605
| +30% | +$147K |
2017 Q2
1 quarter
|
|
48
Mondelez International
MDLZ
$81.4B
| $647K | 0.28% |
15,900
+10,000
| +169% | +$425K |
2013 Q2
17 quarters
|
|
|
SBCP
49
DELISTED
Sunshine Bancorp, Inc
SBCP
| $646K | 0.28% |
27,800
| – | – |
2014 Q3
12 quarters
|
|
50
IBM
IBM
$217B
| $622K | 0.27% |
4,481
| – | – |
2015 Q1
10 quarters
|
|
Similar funds
FA
KCP
HCIA
ISG
TPCM
DCM
MCL
DVC
David M. Knott's Q3 2017 Portfolio in Review
As of Q3 2017, David M. Knott held 114 positions worth $234M, down 2.4% from $240M the previous quarter. Its ten largest holdings account for 77% of the portfolio.
David M. Knott withdrew a net $22.7M in Q3 2017, closing 6 positions and reducing 9 holdings. Its most notable exit was Allergan plc, an estimated $2.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 73% a quarter earlier, followed by Financials and Technology.
Against the trend, David M. Knott opened a new position in Atlas Corp. worth $993K.
- David M. Knott's largest Q3 2017 buy was Atlas Corp.: 140,000 shares worth $993K.
- David M. Knott added most to DuPont de Nemours in Q3 2017, an estimated $1.24M increase.
- David M. Knott's biggest Q3 2017 reduction was Ligand Pharmaceuticals, cutting an estimated $25.4M.
- David M. Knott fully exited Allergan plc in Q3 2017, selling an estimated $2.3M.
- David M. Knott's ten largest holdings make up 77% of its $234M portfolio in Q3 2017.
- David M. Knott opened 24 new positions and closed 6 in Q3 2017.
- David M. Knott's portfolio value fell 2.4% quarter-over-quarter to $234M.
Based on David M. Knott's 13F filing for Q3 2017, filed 13 Nov 2017.